Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical review
Mostafa A. Mansour, Asmaa M. AboulMagd, Samar H. Abbas, Hamdy M. Abdel‐Rahman, Mohamed Abdel‐Aziz
Abstract
a non-irreversible mechanism. This review covers the fourth-generation EGFR-TKIs' most recent design with their essential binding interactions, the clinical difficulties, and the potential outcomes of treating patients with EGFR mutation C797S resistant to third-generation EGFR-TKIs was also discussed. Moreover, the utilization of various therapeutic strategies, including multi-targeting drugs and combination therapies, has also been reviewed.
Topics & Concepts
Lung cancerCancer researchMutationMedicineChemistryBiologyOncologyGeneticsGeneProtein Degradation and InhibitorsLung Cancer Treatments and MutationsPeptidase Inhibition and Analysis